Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT06617923
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Fallopian Tube Cancer
  • Ovary Cancer
  • Primary Peritoneal Cavity Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Senaparib — DRUG
    Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
  • Temozolomide — DRUG
    Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.

Study Details

This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.

Key Dates

Start date
Feb 6, 2025
Status verified
Oct 2025
Primary completion
Oct 31, 2027
Completion
Dec 31, 2029

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Senaparib 80mg Temozolomide 20mg

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: 3 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410
Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce
[email protected]
410-955-8804
University of Pennsylvania/Abramson Cancer CenterPhiladelphiaPennsylvania19104
Andrea Standish, RN, BSN
[email protected]
215-662-2419

Find similar trials in Baltimore, MD

By research site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MDUniversity of Pennsylvania/Abramson Cancer Center· Philadelphia, PA

Related Studies